profit from every €100 of sales.

RHÖN-Klinikum
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2021 to 2024.
You pay €22.39 for every €1 of profit it makes in a year.
It holds more cash than debt.
Money in, money out
What RHÖN-Klinikum sold, what it kept, and what it did with the cash.
Sales went from €1.40 billion in 2021 to €1.60 billion in 2024, with €43.4 million of profit last year.
RHÖN-Klinikum vs. similar companies
RHÖN-Klinikum grows in the middle of these 5 and is priced in the middle for its profits.
| Company | Profit from €100 of sales | Sales growth a year | Price per €1 of profit |
|---|---|---|---|
RHÖN-Klinikum | 22.4× · Fair price | ||
HCA Healthcare | 15.4× · Fair price | ||
Fresenius SE & Co. KGaA | 23.9× · Fair price | ||
IHH Healthcare Berhad | 34.3× · Expensive | ||
Rede D'Or São Luiz | 16.2× · Fair price |
AI analysis
An AI analyst reads RHÖN-Klinikum's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of EUR | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| 1,402 | 1,446 | 1,464 | 1,596 | |
| 198 | 199 | 149 | 172 | |
| 30 | 36 | 30 | 37 | |
| 101 | 107 | 117 | 122 | |
| 28 | 25 | 39 | 43 | |
| 0.42 | 0.38 | 0.58 | 0.65 | |
| 14.1% | 13.8% | 10.2% | 10.8% | |
| 2.1% | 2.5% | 2.0% | 2.4% | |
| 2.0% | 1.7% | 2.6% | 2.7% |
Balance sheet
| In millions of EUR | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 1,666 | 1,705 | 1,771 | 1,856 |
| Cash | 126 | 77 | 206 | 280 |
| Total debt | 160 | 158 | 150 | 150 |
| Total liabilities | 441 | 454 | 490 | 531 |
| 1,198 | 1,224 | 1,252 | 1,296 | |
| 67 | 67 | 67 | 67 | |
| 1.6% | 1.9% | 2.6% | 2.9% | |
| 2.4% | 2.1% | 3.1% | 3.3% |
Cash flow
| In millions of EUR | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| 98 | 60 | 109 | 128 | |
| 78 | 58 | 63 | 70 | |
| 20 | 2 | 46 | 57 | |
| Dividends paid | – | – | 10 | – |
| – | – | – | – | |
| – | – | – | – |
Valuation
- 22.4×
- –
- 1.43
- 0.7×
- 0.6×
- 17.0×
- 6.9×
- 5.9%
- 4.5%
- –
Profitability
- 10.8%
- 2.4%
- 2.7%
- –
- 2.9%
- 2.2%
- –
- –
- –
- –
Growth
- +4.4%
- +15.7%
- –
- –
- +0.0%
Financial health
- -1.1×
- 0.12
- –
- 17.5×
- 2.23
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Questions about RHÖN-Klinikum
Is RHÖN-Klinikum a good stock to buy?
A business with weak numbers at a fair price. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the RHÖN-Klinikum AI analysis
What does RHÖN-Klinikum do?
RHÖN-KLINIKUM Aktiengesellschaft, together with its subsidiaries, provides in-patient, semi-patient, and outpatient healthcare services in Germany. The company operates acute hospitals, medical care centers, and rehabilitation hospitals. It is in Medical Care Facilities, based in Bad Neustadt an der Saale, Germany, with 19,184 employees.
Is RHÖN-Klinikum stock halal?
Questionable. RHÖN-Klinikum sits in a grey zone: short-term investments may earn interest; type not reported. How we check
Who are RHÖN-Klinikum's competitors?
The largest listed companies in the same industry are HCA Healthcare, Fresenius SE & Co. KGaA, IHH Healthcare Berhad and Rede D'Or São Luiz. The peers table on this page compares their profit, growth and price with RHÖN-Klinikum's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.



